MED is pivoting to metabolic health, using clinical data and new products to address root causes beyond GLP-1 weight loss.

Baltimore-based Medifast opened a research and development hub in Owings Mills on Tuesday with plans to develop new products and expand from weight management into the larger $230 billion health and ...

Medifast, Inc. (NYSE: MED) today announced a planned leadership transition designed to provide continuity and stability as ...

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions The latest update is out from Medifast ( (MED) ).

Medifast (MED) announced a planned leadership transition. Medifast chairman and CEO Dan Chard has informed the board of directors that he plans to ...

Medifast enjoyed record profits immediately after the pandemic. The emergence of GLP-1 medications has driven revenue, income, and the number of active Optavia coaches down. Management has laid out a ...

The outgoing CEO turned the Baltimore company into a $1 billion operation. Now his successor is tasked with turning it around ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The latest layoffs come after ...

Medifast is ideal for dieters who haven’t gotten results from a traditional healthy meal plan or are considering surgery to achieve weight loss. Medifast is a simple weight loss program that features ...